Bin Li, Yang Yuxiao, Wang Feiyu, Wang Rong, Fei Hongxin, Duan Siliang, Huang Linling, Liao Na, Zhao Shimei, Ma Xinbo
Department of Biochemistry and Molecular Biology, Medical College, Guangxi University of Science and Technology, Liuzhou, China.
Second Clinical Medical College, Medical College, Guangxi University of Science and Technology, Liuzhou, China.
Front Bioeng Biotechnol. 2022 Jul 22;10:960501. doi: 10.3389/fbioe.2022.960501. eCollection 2022.
Biopolymer silk fibroin (SF) is a great candidate for drug carriers characterized by its tunable biodegradability, and excellent biocompatibility properties. Recently, we have constructed SF-based nano-enabled drug delivery carriers, in which doxorubicin (Dox) and atovaquone (Ato) were encapsulated with Arg-Gly-Asp-SF-Polylactic Acid (RSA) to form micellar-like nanoparticles (RSA-Dox-Ato NPs). The RGD peptide was decorated on micellar-like nanoparticles, promoting tumor accumulation of the drug. Meanwhile, Ato, as a mitochondrial complex III inhibitor inhibiting mitochondrial respiration, would reverse the hypoxia microenvironment and enhance chemotherapy in the tumor. , the biopolymer alone showed extremely low cytotoxicity to 4T1 cell lines, while the RSA-Dox-Ato demonstrated a higher inhibition rate than other groups. Most significantly, the ROS levels in cells were obviously improved after being treated with RSA-Dox-Ato, indicating that the hypoxic microenvironment was alleviated. Eventually, SF-based targeted drug carrier provides biocompatibility to reverse hypoxia microenvironment for enhancing chemotherapy, strikingly suppressing tumor development, and thereby suggesting a promising candidate for drug delivery system.
生物聚合物丝素蛋白(SF)是一种理想的药物载体,具有可调节的生物降解性和出色的生物相容性。最近,我们构建了基于SF的纳米药物递送载体,其中阿霉素(Dox)和阿托伐醌(Ato)与精氨酸-甘氨酸-天冬氨酸-丝素蛋白-聚乳酸(RSA)包裹形成胶束状纳米颗粒(RSA-Dox-Ato NPs)。RGD肽修饰在胶束状纳米颗粒上,促进药物在肿瘤中的积累。同时,Ato作为线粒体复合物III抑制剂抑制线粒体呼吸,可逆转缺氧微环境并增强肿瘤化疗效果。单独的生物聚合物对4T1细胞系显示出极低的细胞毒性,而RSA-Dox-Ato表现出比其他组更高的抑制率。最显著的是,用RSA-Dox-Ato处理后细胞内活性氧水平明显提高,表明缺氧微环境得到缓解。最终,基于SF的靶向药物载体提供生物相容性以逆转缺氧微环境,增强化疗效果,显著抑制肿瘤发展,从而表明其是一种有前景的药物递送系统候选物。